Barraquer-Simons Syndrome

Barraquer-Simons syndrome is a very rare condition where body fat slowly disappears from the upper half of the body—first the face, then the neck, shoulders, arms, chest, and sometimes upper abdomen. The lower body (hips and legs) is usually spared and may even look fuller later in life, especially in women. The fat loss is bilateral (both sides) and follows a head-to-toe (cephalocaudal) pattern. Many people develop low blood levels of a protein called complement C3 because their immune system makes an antibody called C3 nephritic factor (C3NeF) that keeps part of the complement system “switched on.” This chronic activation can injure fat cells and, years later, can also affect the kidneys in some patients. NCBIPubMedBioMed Central

In many patients, the immune system makes C3NeF. This antibody drives the alternative complement pathway to stay active. Complement proteins then attack the surface of fat cells (adipocytes). Over time, the fat cells in the upper body are damaged and lost. The same overactive complement pathway may later damage the kidney filters (glomeruli), causing protein in urine, swelling, and high blood pressure if not treated. PMCPubMed

Barraquer-Simons syndrome (BSS) is a very rare condition where a person slowly loses the layer of normal fat (subcutaneous fat) from the upper half of the body—starting with the face, then the neck, shoulders, arms, chest, and upper abdomen. The lower body—buttocks and legs—usually keeps its fat or may even look fuller, so the body looks top-thin and bottom-normal or bottom-full. Doctors call this top-to-bottom spread a “cephalocaudal” or “cephalothoracic” pattern. The fat loss often begins in childhood or the early teen years. Many patients have low blood levels of the complement protein C3 due to immune system over-activity, and some later develop kidney disease related to that same immune pathway. OrphaPMC+1UT Southwestern

---

Other names

Doctors and articles may use several names that mean the same thing:

• Acquired partial lipodystrophy (APL)

• Barraquer-Simons syndrome (BSS)

• Cephalothoracic lipodystrophy

• Progressive partial lipodystrophy

All of these describe the same clinical picture: progressive loss of upper-body fat with relative sparing of the lower body. OrphaPMCWikipedia

---

Types

There is no universally fixed sub-typing system for BSS, but in real-world practice clinicians often think about patterns or variants that help with monitoring and counseling:

1. Classic BSS without kidney disease. Fat loss follows the typical face-first pattern, C3 may be low or normal, and the person does not show signs of kidney trouble. Orpha

2. BSS with complement dysregulation (C3NeF-positive). The person has low C3 and C3 nephritic factor (C3NeF)—an autoantibody that keeps the alternative complement pathway “on.” This group carries a higher risk of C3 glomerulopathy (a kidney disease). PMCPubMedRevista Nefrología

3. BSS with kidney involvement. The same fat-loss pattern is present, and there is hematuria/proteinuria or a biopsy-proven C3 glomerulopathy; prognosis is shaped mainly by kidney health. BioMed CentralPubMed

4. BSS with associated autoimmune disease. Some patients show other autoimmune features (for example, autoimmune thyroid disease or positive autoimmune panels), reflecting broader immune activation. PubMedBioMed Central

5. BSS with lower-body adipose hypertrophy after puberty (mostly in women). The upper body becomes thin, while hips and legs may look fuller, creating regional disproportion. BioMed Central

Note: These patterns are meant to guide monitoring (especially for kidneys and autoimmunity) and counseling. They are not formal subtypes used in every textbook.

---

Causes

BSS is acquired (not inherited in a simple way). The exact cause is unknown, but research shows immune system changes, especially complement pathway dysregulation, play a major role. Below are 20 causes/associations/triggers described in the literature. Think of them as drivers or linked factors, not one single cause for everyone.

1. Alternative complement pathway over-activation. The body’s “complement” system, which fights germs, stays over-active, especially the alternative pathway, and damages fat tissue. C3 becomes low in the blood. PMC

2. C3 nephritic factor (C3NeF) autoantibody. This is an autoantibody that keeps complement turned on. It is common in APL and links the fat loss to possible kidney disease. PMCPubMed

3. C3 hypocomplementemia. Many patients show low C3 levels, a blood sign that complement is being consumed. OrphaRevista Nefrología

4. C3 glomerulopathy link. The same complement problem can affect the kidneys, causing C3 glomerulopathy years after fat loss starts. PubMed

5. Childhood or early-teen onset. Onset often around 8–10 years; some reports suggest a preceding viral illness before fat loss begins. UT Southwestern

6. Post-infectious trigger. Case series note fat loss after an acute viral infection; the infection may trigger the immune shift that activates complement. UT Southwestern

7. Autoimmune clustering. Some patients show other autoimmune conditions (e.g., autoimmune thyroid disease), suggesting a shared immune tendency. PubMed

8. Autoimmune serology signals. Research cohorts of BSS show autoantibodies or immune abnormalities, strengthening the immune-mediated model. BioMed Central

9. Classical pathway activation in select cases. While most focus is on the alternative pathway, small series found classical pathway activation in some patients—reminding us that immune behavior can vary. PubMed

10. Genetic susceptibility in complement regulation (rare). Rare variants in complement regulators (e.g., factor H) or C3 may predispose a person, but BSS is not a straightforward genetic disease. (This is an inference from complement literature; clinicians watch for it when kidney disease is present.) PubMed

11. Immune complex activity. Abnormal complement activation can involve immune complexes, which may damage tiny blood vessels in fat tissue. PubMed

12. Local adipocyte injury from complement attack. Over-active complement can damage fat cells or their micro-environment, leading to loss of subcutaneous fat in affected regions. PMC

13. Female predominance in reports. Many case series describe more females with BSS, possibly due to immune differences, though exact reasons are unclear. (Pattern discussed across reviews.) PMC

14. Association with low leptin is milder than in generalized lipodystrophy. BSS usually has less severe leptin deficiency than generalized forms, which shapes symptoms and treatment response. BioMed Central

15. Lower risk of severe insulin resistance (compared with generalized forms). Because the fat loss is partial, metabolic problems like severe insulin resistance are often less prominent. BioMed Central

16. Pregnancy or hormonal life events as temporal associations in case reports. Individual reports note onset or change around pregnancy, but this is not a proven cause—more a timing association. Cosmoderma

17. Link to renal prognosis. In practical terms, the kidney link is not a “cause” of fat loss, but it is a downstream effect of the same immune problem and crucial to long-term outcomes. BioMed Central

18. Potential environmental triggers. Because it is acquired, doctors consider environmental immune triggers (infections most commonly). Direct proof for specific agents is limited. UT Southwestern

19. Idiopathic in many. In a significant share, no clear trigger is identified even after testing; the condition is labeled idiopathic. National Organization for Rare Disorders

20. Heterogeneity across patients. Not every patient follows the same immune pattern. Some have C3NeF, some do not; some develop kidney disease, others never do—showing multiple paths to the same outward look. BioMed Central

---

Symptoms

1. Gradual thinning of the face. Cheeks look hollow, the jawline becomes sharp, and the eyes may look more sunken as facial fat melts away. The change is usually slow over months to years. PMC

2. Fat loss in the neck and shoulders. The neck looks slender; collarbones and shoulder contours are more visible. PMC

3. Thin arms and upper chest. The upper limbs and chest wall lose their soft layer; muscles and veins may look more obvious. PMC

4. Upper-abdomen flattening. The area above the belly button can look lean because the fat there is reduced. PMC

5. Lower body looks relatively full. Hips and legs often keep fat; in some women, the lower body may look fuller after puberty, which increases the body size mismatch. BioMed Central

6. Body disproportions in clothing fit. Shirts feel loose while pants fit normally or snug—reflecting the top-thin/bottom-normal pattern. Orpha

7. Visible veins on the upper chest or arms. With less fat under the skin, superficial veins can look more obvious. PMC

8. Possible fatigue or reduced endurance. This may relate to body-image stress, general health, or—if present—hidden kidney problems.

9. Urine changes if kidneys are involved. Foamy urine (protein), tea-colored urine (blood), or swelling in the legs can occur when kidney disease develops. PubMed

10. Swelling (edema) from kidney disease. If protein leaks from the kidneys, the legs or face may swell; blood pressure can rise. PubMed

11. Milder metabolic symptoms than generalized lipodystrophy. Severe hunger, extreme insulin resistance, or pancreatitis are less common in BSS than in generalized forms. BioMed Central

12. Psychosocial impact. Changes in face and body shape can affect self-image and social comfort, especially when onset is during school years.

13. Dry skin or skin texture changes over lean areas. With fat loss, skin may feel thinner over bony points.

14. Weight on the scale may not change much. Fat shifts by region; total body weight can be near normal, confusing families early on. Orpha

15. Sometimes completely asymptomatic. Some people feel well and only discover the condition during a routine exam or when urine protein is found. Revista Nefrología

---

Diagnostic tests

A) Physical exam

1. Pattern-focused inspection. The doctor looks for the typical top-down loss of fat: face → neck → shoulders/arms → chest/upper abdomen, with lower body sparing. This pattern is the clinical key. PMC

2. Blood pressure measurement. High blood pressure can be a sign of kidney involvement in C3 glomerulopathy; it needs tracking over time. PubMed

3. Edema check (pressing the shin or ankle). Pitting edema suggests significant protein loss in urine (nephrotic-range proteinuria). PubMed

4. Skin and vein observation. With less subcutaneous fat, superficial veins and bony points are more visible—supporting the clinical impression. PMC

B) Manual tests (bedside measurements)

5. Skinfold thickness with calipers. Measuring skinfolds at standard sites (triceps, subscapular, suprailiac) shows reduced thickness in the upper body with relative preservation in the legs.

6. Mid-upper arm circumference (MUAC). A simple tape measure reflects soft-tissue loss in the arms and can be tracked over time.

7. Waist-to-hip ratio. This simple ratio helps describe regional fat distribution; in BSS the hip measurement may be relatively preserved.

8. Serial photos with consent. Standardized, reproducible photos taken over months help document progression and support clinical decisions.

C) Lab & pathological tests

9. Serum C3 (complement) level. Often low in BSS, reflecting ongoing alternative complement pathway activation. This is a high-value screening marker. OrphaRevista Nefrología

10. C3 nephritic factor (C3NeF) assay. Detects the autoantibody that keeps complement turned on; positivity supports BSS linked to complement dysregulation and alerts clinicians to possible kidney risk. PMC

11. C4 and broader complement panel. Helps define which complement pathway is active. Most BSS centers on the alternative pathway, but patterns can vary. PubMed

12. Urinalysis (dipstick and microscopy). Screens for protein and blood in urine—early signs of C3 glomerulopathy. PubMed

13. Urine protein quantification (ACR or 24-hour). Measures how much protein is leaking; guides kidney disease staging. PubMed

14. Serum creatinine and eGFR. Checks kidney function; important for baseline and follow-up. PubMed

15. Lipid panel, fasting glucose, HbA1c, liver enzymes, and leptin. Screens for metabolic effects (usually milder in BSS than in generalized forms) and for fatty liver if suspected. Leptin may be less reduced in BSS than in generalized forms. BioMed Central

16. Autoimmune serology (e.g., ANA; thyroid antibodies if indicated). Looks for co-existing autoimmune disease, which can travel with BSS in some patients. PubMedBioMed Central

17. Skin/subcutaneous fat biopsy (selected cases). Histology can show loss of adipocyte lobules and other changes; it helps when the presentation is atypical or to rule out other causes of lipoatrophy. Cosmoderma

18. Kidney biopsy (when kidney disease is suspected). Provides a definitive diagnosis of C3 glomerulopathy if proteinuria/hematuria or declining function is present; guides management and prognosis. PubMed

D) Electrodiagnostic tests

19. Nerve conduction studies / EMG (only if there are neurologic complaints). These are not routine for BSS. They are used only when a patient has separate neuropathy or myopathy symptoms to exclude other conditions that also change body shape.

20. Autonomic function testing (only if indicated). Also not routine for BSS. Considered when there are autonomic symptoms (e.g., unexplained fainting), to rule out other disorders.
    Why include these two? Your requested category lists “Electrodiagnostic.” For BSS, these tests do not diagnose the syndrome; they are adjuncts used in special situations.

E) Imaging tests

21. Whole-body MRI or regional MRI fat mapping. Shows where fat is lost and where it is preserved, creating a visual map of the cephalocaudal pattern in BSS; useful for documentation and research.

22. DXA (dual-energy X-ray absorptiometry) body composition. Quantifies fat mass by region (arms, trunk, legs) and provides an objective baseline to track change over time.

Non-pharmacological treatments

1. Medical nutrition therapy (MNT)
   Description: A diet plan tailored to triglycerides, glucose, and kidney status.
   Purpose: Control blood sugar and blood fats; protect kidneys.
   Mechanism: Low glycemic load, adequate protein, controlled saturated fat and sodium.
   Benefits: Lower triglycerides and HbA1c; less strain on kidneys. NCBI

2. Structured aerobic exercise (physiotherapy)
   Description: 150–300 minutes/week of moderate walking, cycling, or swimming.
   Purpose: Improve insulin sensitivity and lipid profile.
   Mechanism: Increased muscle glucose uptake; better fat handling in liver.
   Benefits: Lower triglycerides, improved energy and mood. NCBI

3. Progressive resistance training (physiotherapy)
   Description: 2–3 sessions/week targeting major muscle groups.
   Purpose: Build lean mass to improve metabolism.
   Mechanism: Muscle hypertrophy increases resting glucose disposal.
   Benefits: Better glycemic control and function in daily tasks. NCBI

4. Posture and cervical-shoulder mobility therapy (physiotherapy)
   Description: Physical therapy to maintain neck/shoulder range.
   Purpose: Reduce discomfort from altered fat distribution.
   Mechanism: Scapular stabilization, stretching.
   Benefits: Less muscle tension; improved appearance/comfort.

5. Core-stability training (physiotherapy)
   Purpose: Support trunk mechanics as body contours change.
   Mechanism: Strengthens deep core muscles.
   Benefits: Balance, back comfort, confidence.

6. Breathing exercises (physiotherapy / mind-body)
   Description: Diaphragmatic breathing, 5–10 minutes/day.
   Purpose: Stress control; adjunct to blood pressure control.
   Mechanism: Parasympathetic activation.
   Benefits: Lower perceived stress; better adherence to care.

7. Yoga or tai chi (mind-body)
   Purpose: Gentle whole-body conditioning and stress relief.
   Mechanism: Flexibility, vagal tone.
   Benefits: Sleep, mood, and metabolic behavior support.

8. Cognitive behavioral therapy (CBT) / body-image counseling (educational/psychological)
   Description: Short-term therapy focusing on coping skills.
   Purpose: Manage anxiety/depression about facial changes.
   Mechanism: Reframing thoughts; behavior activation.
   Benefits: Better quality of life and treatment adherence.

9. Patient/family education (educational therapy)
   Purpose: Understand complement/kidney monitoring, lipids, warning signs.
   Mechanism: Teach action plans for high glucose, proteinuria, or swelling.
   Benefits: Earlier detection; fewer complications. GARD Information Center

10. Renal self-care education (educational)
    Purpose: Sodium/protein guidance, nephrotoxin avoidance.
    Mechanism: Practical kidney-safe choices.
    Benefits: Slower progression if kidney disease develops. GARD Information Center

11. Sleep hygiene program
    Purpose: 7–9 hours/night to support metabolism and mood.
    Mechanism: Hormonal regulation (leptin/ghrelin/insulin).
    Benefits: Better appetite control and energy.

12. Smoking cessation support
    Purpose: Reduce cardiovascular and renal risk.
    Mechanism: Improves endothelial and kidney health.
    Benefits: Lower BP and event risk.

13. Alcohol-use moderation plan
    Purpose: Protect liver and triglycerides.
    Mechanism: Reduces hepatic fat synthesis.
    Benefits: Lower TG, fewer pancreatitis flares in severe hypertriglyceridemia.

14. Low-impact interval walking program (physiotherapy)
    Purpose: Option for beginners or joint pain.
    Mechanism: Alternating brisk/easy pace aids insulin sensitivity.
    Benefits: More accessible than continuous exercise.

15. Balance & fall-prevention training (physiotherapy)
    Purpose: Confidence with altered body proportions.
    Mechanism: Proprioception drills.
    Benefits: Reduces falls; increases activity.

16. Sun-smart skin care & camouflage techniques
    Purpose: Reduce attention to facial fat loss.
    Mechanism: Makeup, hairstyles, dermatology advice.
    Benefits: Confidence; UV protection.

17. Peer support group / rare-disease community
    Purpose: Emotional and practical tips.
    Mechanism: Shared experience reduces isolation.
    Benefits: Better mental health and coping.

18. Workplace/school accommodations
    Purpose: Flex time for medical visits and labs.
    Mechanism: Admin letters, care plans.
    Benefits: Reduced stress; improved adherence.

19. Financial counseling for rare-disease care
    Purpose: Navigate coverage for labs, imaging, fillers, or specialty drugs.
    Mechanism: Social worker/pharmacist support.
    Benefits: Fewer interruptions in therapy.

20. Registered-dietitian–led weight-neutral counseling
    Purpose: Focus on labs, energy, kidney health—not weight alone.
    Mechanism: Non-stigmatizing nutrition care.
    Benefits: Sustainable change.

21. Mindfulness-based stress reduction (mind-body)
    Purpose: Cope with chronic illness uncertainty.
    Mechanism: Attention training lowers stress reactivity.
    Benefits: Improved sleep and BP.

22. Dermatology-guided facial hyaluronic acid fillers
    Purpose: Soften hollows/contours.
    Mechanism: Volume replacement in subcutaneous planes.
    Benefits: Immediate cosmetic improvement; temporary, repeatable. NCBI

23. Poly-L-lactic acid (PLLA) biostimulatory fillers
    Purpose: Gradual collagen stimulation for volume.
    Mechanism: Neocollagenesis over months.
    Benefits: Longer-lasting contour support (used in lipodystrophy). NCBI

24. Autologous fat grafting (lipofilling)
    Purpose: More natural, larger-volume facial restoration.
    Mechanism: Transfer of patient’s own fat; some long-term persistence.
    Benefits: Durable aesthetic gains; may need staged sessions. PubMed

25. Custom combination plans
    Purpose: Blend diet, exercise, counseling, and cosmetic steps.
    Mechanism: Multidisciplinary clinic (endocrine, nephrology, derm/plastics).
    Benefits: Best overall health and quality of life. NCBI

---

Drug treatments

Always individualized by specialists. Adult dosing ranges shown; pediatric regimens differ. Monitor kidneys and liver. Many patients with APL have milder metabolic issues than other lipodystrophies, so not every medicine is needed. Citations support class usefulness in lipodystrophy or kidney risk.

1. Metformin (biguanide)
   Dose/time: 500–2,000 mg/day with meals.
   Purpose: Improve insulin resistance.
   Mechanism: Lowers hepatic glucose production; improves peripheral uptake.
   Side effects: GI upset; rare lactic acidosis (renal caution). NCBI

2. GLP-1 receptor agonists (e.g., semaglutide)
   Dose/time: Weekly or daily per label.
   Purpose: Lower HbA1c; reduce hepatic fat and appetite.
   Mechanism: Incretin pathway; slows gastric emptying.
   Side effects: Nausea; gallbladder risk; pancreatitis warnings. NCBI

3. SGLT2 inhibitors (e.g., empagliflozin)
   Dose/time: Once daily.
   Purpose: Glucose control; kidney and heart protection in diabetes/proteinuria.
   Mechanism: Renal glucose excretion; hemodynamic renal effects.
   Side effects: Genital infections; rare ketoacidosis. NCBI

4. Basal/bolus insulin
   Dose/time: Titrated to glucose.
   Purpose: Control hyperglycemia when oral therapy insufficient.
   Mechanism: Replaces insulin.
   Side effects: Hypoglycemia; weight change. NCBI

5. Fenofibrate (fibrate)
   Dose/time: 145 mg daily (typical).
   Purpose: Lower very high triglycerides; pancreatitis prevention.
   Mechanism: PPAR-α activation increases TG clearance.
   Side effects: Myalgia; LFT rise; renal dose adjust. NCBI

6. High-dose omega-3 ethyl esters (EPA/DHA)
   Dose/time: 2–4 g/day EPA+DHA.
   Purpose: Lower triglycerides.
   Mechanism: Reduces hepatic VLDL production.
   Side effects: Fishy belching; bleeding risk at high doses. NCBI

7. Statins (e.g., atorvastatin)
   Dose/time: Nightly or daily per agent.
   Purpose: Lower LDL-C; reduce CV risk.
   Mechanism: HMG-CoA reductase inhibition; upregulate LDL receptors.
   Side effects: Myopathy; LFT elevations. NCBI

8. ACE inhibitors (e.g., lisinopril)
   Dose/time: Daily; titrate to BP/proteinuria.
   Purpose: Kidney protection if albuminuria develops.
   Mechanism: Lowers intraglomerular pressure.
   Side effects: Cough; hyperkalemia; teratogenic. GARD Information Center

9. ARBs (e.g., losartan)
   Purpose: Alternative to ACEi for proteinuria/BP.
   Side effects: Hyperkalemia; renal function monitoring. GARD Information Center

10. Metreleptin (recombinant leptin) – specialist/off-label in partial lipodystrophy
    Dose/time: Weight-based daily SC; only FDA-approved for generalized lipodystrophy; PL use is off-label in select severe metabolic cases.
    Purpose: Improve severe hypertriglyceridemia/insulin resistance in leptin-deficient lipodystrophy.
    Mechanism: Replaces missing leptin, improving insulin sensitivity and liver fat.
    Side effects: Headache, nausea; neutralizing antibodies (rare); T-cell lymphoma risk noted in generalized forms with long-standing immunosuppression. CenterWatchPMCJunior Chamber InternationalPubMed

11. Ezetimibe
    Purpose: Additional LDL lowering when statin not enough.
    Mechanism: Blocks intestinal cholesterol absorption.
    Side effects: Usually mild GI effects. NCBI

12. Eculizumab (C5 inhibitor) – nephrology-led
    Dose/time: IV induction then q2w; meningococcal vaccination required.
    Purpose: For selected patients with C3 glomerulopathy not controlled by standard care.
    Mechanism: Blocks terminal complement pathway (C5→MAC).
    Side effects: Serious infection risk; cost. Evidence mixed and case-based. ScienceDirect

13. Mycophenolate mofetil – nephrology-led
    Purpose: Sometimes used for complement-mediated glomerulopathy.
    Mechanism: Lymphocyte proliferation inhibitor.
    Side effects: GI upset, cytopenias, infection risk. ScienceDirect

14. Corticosteroids – short courses only if indicated by specialists
    Purpose: Select immune kidney or autoimmune flares; not for fat loss.
    Mechanism: Broad anti-inflammatory.
    Side effects: Hyperglycemia, weight, BP, infection risk. PubMed

15. Rituximab – specialist-guided
    Purpose: Certain autoimmune co-conditions or glomerulopathy phenotypes.
    Mechanism: Anti-CD20 B-cell depletion.
    Side effects: Infusion reactions; infection risk. ScienceDirect

---

Dietary molecular supplements

1. Omega-3 EPA/DHA (2–4 g/day EPA+DHA) – lowers triglycerides; reduces liver fat production. NCBI

2. Soluble fiber (psyllium 5–10 g/day) – slows glucose absorption; improves lipids by binding bile acids. NCBI

3. Vitamin D (per labs, often 800–2,000 IU/day) – supports general metabolic and immune health when deficient. NCBI

4. Magnesium (200–400 mg/day) – may aid insulin sensitivity and BP (renal dose caution). NCBI

5. Alpha-lipoic acid (300–600 mg/day) – antioxidant; supports insulin signaling (mixed evidence). NCBI

6. Probiotics (per label) – modest triglyceride and inflammation effects in some studies. NCBI

7. Plant sterols/stanols (1.6–2.4 g/day) – lower LDL by blocking absorption. NCBI

8. Coenzyme Q10 (100–200 mg/day) – may help statin-associated myalgias; mitochondrial support. NCBI

9. Niacinamide (not niacin for lipids) – cellular NAD+ support; avoid high-dose niacin for triglycerides unless supervised (glucose and liver effects). NCBI

10. Curcumin (up to ~1 g/day) – anti-inflammatory adjunct; variable bioavailability. NCBI

Note: Supplements do not reverse fat loss and can interact with medicines; confirm safety, especially with kidney involvement.

---

Regenerative / stem-cell”-type drugs

There are no approved stem-cell drugs to restore lost fat in Barraquer-Simons syndrome. Options below are specialist or research-level therapies that target hormones or complement and are used for complications, not to regrow fat.

1. Metreleptin (recombinant leptin) – hormone replacement that improves insulin sensitivity and triglycerides in lipodystrophy; approved for generalized, off-label in severe partial cases. CenterWatchPMCPubMed

2. Eculizumab (C5 inhibitor) – for selected C3 glomerulopathy; reduces terminal complement activation; requires vaccination and close monitoring. ScienceDirect

3. Ravulizumab (long-acting C5 inhibitor) – similar mechanism; considered by some centers for C3G on a case-by-case basis. ScienceDirect

4. Iptacopan (factor B inhibitor) – an oral alternative-pathway blocker; under evaluation/early approvals for complement diseases, with research interest in C3G. Discuss trial access. ScienceDirect

5. Mycophenolate mofetil – immune modulation for certain glomerulopathy phenotypes; evidence mixed. ScienceDirect

6. Rituximab – B-cell depletion for autoimmune overlap or certain kidney patterns. ScienceDirect

Why no stem-cell pills? Current science cannot safely and predictably rebuild the specific lost subcutaneous fat in this syndrome. Surgical fat grafting (below) provides volume restoration. PubMed

---

Surgeries/procedures

1. Autologous fat grafting (lipofilling) – Harvest fat (often from thighs/hips), process, and inject into facial hollows. Why: Restore natural contours with your own tissue; may need multiple sessions. PubMed

2. Hyaluronic acid fillers – Office injections for midface, temples, periorbital hollows. Why: Immediate, reversible soft-tissue volume. NCBI

3. Poly-L-lactic acid fillers – Series of sessions that stimulate collagen over months. Why: Longer-term global volumization in lipodystrophy. NCBI

4. Combination filler–fat approaches – Stage 1 fat grafting, later fine-tune with fillers. Why: Balance durability and precision. PubMed

5. Body-contouring (select patients) – If lower-body fat hypertrophy creates imbalance, liposculpture by experienced surgeons. Why: Symmetry and comfort (case-by-case). BioMed Central

---

Prevention tips

Because many cases are immune-mediated, we cannot fully “prevent” the syndrome. But you can reduce complication risks:

1. Annual kidney checks: urine albumin/creatinine, serum creatinine, BP. GARD Information Center

2. Maintain healthy lipids: diet + activity; use TG-lowering therapy if needed. NCBI

3. Vaccinations up to date; meningococcal vaccine if ever on C5-inhibitors. ScienceDirect

4. Avoid nephrotoxins: NSAID overuse, contrast dye without hydration, herbal unknowns. GARD Information Center

5. Blood pressure control (<130/80 if kidney disease/diabetes). GARD Information Center

6. Limit alcohol to protect liver and triglycerides. NCBI

7. Quit smoking to reduce kidney and cardiovascular risks. NCBI

8. Regular exercise for insulin sensitivity and TG control. NCBI

9. Early evaluation of edema, foamy urine, or rising BP. GARD Information Center

10. Multidisciplinary care (endocrine, nephrology, dermatology/plastics). NCBI

---

When to see doctors

• Now/urgent: Severe belly pain with very high triglycerides (pancreatitis symptoms), new heavy swelling of legs/face, dark or foamy urine, sudden high BP, or shortness of breath. NCBIGARD Information Center

• Soon (days–weeks): Rapid new fat loss in face/upper body; fatigue, rising sugars, or cholesterol; concerns about mood or appearance; planning pregnancy; medication side effects. NCBI

• Routine: Every 6–12 months for labs (lipids, A1c if diabetic risk, kidney tests), BP checks, and skin/cosmetic review if desired. NCBI

---

What to eat” and “what to avoid

Eat more of:

1. High-fiber carbs (oats, lentils, beans, vegetables).

2. Lean proteins (fish, skinless poultry, tofu, pulses).

3. Omega-3-rich fish (salmon, sardines) twice weekly.

4. Unsalted nuts & seeds (portions mindful).

5. Low-fat dairy or fortified alternatives (per kidney status).
   Avoid/limit:

6. Sugary drinks and refined sweets (spike TG/glucose).

7. Highly processed snacks rich in trans/saturated fats.

8. Excess sodium (aim <2 g/day sodium if kidney risk).

9. Heavy alcohol (raises TG; liver risk).

10. Very high-fructose loads (some sweetened juices). NCBI

---

Frequently Asked Questions

1. Is it genetic?
   Most cases are acquired, not inherited. Some lipodystrophies are genetic, but Barraquer-Simons is typically immune-linked. NCBIOrpha

2. What causes the fat loss?
   Often an antibody called C3NeF drives the complement system to attack fat cells in the upper body. PubMed

3. Can the fat grow back by itself?
   Spontaneous regrowth is uncommon. Cosmetic restoration uses fillers or fat grafting. PubMed

4. Will I definitely get kidney disease?
   No. Only a subset develop C3 glomerulopathy/MPGN, often >10 years after onset. Regular urine/BP checks catch it early. GARD Information Center

5. Do all patients get diabetes or severe metabolic problems?
   Not necessarily; compared with other lipodystrophies, metabolic issues may be milder in APL, but screening is still important. BioMed Central

6. Is metreleptin for me?
   It’s approved for generalized lipodystrophy. In partial forms, some centers use it off-label for severe insulin resistance or triglycerides; decisions are individualized. CenterWatchPubMed

7. Are “stem-cell pills” available?
   No approved stem-cell drugs restore fat in this condition. Surgical fat grafting is the practical regenerative option today. PubMed

8. What about new complement drugs?
   C5 and alternative-pathway inhibitors (e.g., eculizumab, ip tacopan) are being used or studied for kidney disease, not for cosmetic fat loss. ScienceDirect

9. Can exercise make fat loss worse?
   No. Exercise helps metabolic health and confidence; it does not drive the pathologic fat loss pattern. NCBI

10. Is it contagious?
    No—this is not an infection.

11. Can children be affected?
    Yes—onset often in childhood or early teens. GARD Information Center

12. What specialists should I see?
    Endocrinologist/metabolic, nephrologist (for kidney monitoring), and dermatology/plastic surgery for appearance support. NCBI

13. Will pregnancy make it worse?
    Data are limited; plan pre-conception counseling to manage lipids, glucose, and kidney monitoring during pregnancy. NCBI

14. Are fillers safe for me?
    When placed by experienced clinicians, HA and PLLA fillers are commonly used in lipodystrophy; periodic maintenance is expected. NCBI

15. What is the long-term outlook?
    With regular monitoring and risk-factor control, many people do well. Kidney health is the most important long-term issue to track. GARD Information Center

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 02, 2025.